Key result
The safety and tolerability of open-label daclizumab in multiple sclerosis patients was assessed, but no results are reported in the abstract.
Why the study?
Does daclizumab have acceptable safety and tolerability in multiple sclerosis patients who fail first-line therapy?
Observational
Open-label
Does daclizumab have acceptable safety and tolerability in multiple sclerosis patients who fail first-line therapy?
No results reported from this cohort; leaves open daclizumab safety in MS after first-line failure.
BACKGROUND: Daclizumab is a humanized monoclonal antibody (mAb) that blocks the interleukin-2 receptor alpha subunit (IL-2R-alpha chain; CD25) expressed on activated T cells leading to the inhibition of T-cell expansion, thus strongly reduces brain inflammation in patients with multiple sclerosis (MS). Another mechanism is significant expansion of CD56 (bright) natural killer (NK) cells that in turn inhibit T-cell survival. OBJECTIVE: At the Partners MS center, we have been using Daclizumab in an open-label fashion in patients who fail first line therapy or non-standard immunosuppressive treatment. Our aim was to assess its safety and tolerability in our patient population.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2008) conducted an observational in Multiple sclerosis. Daclizumab was evaluated on Safety and tolerability. The safety and tolerability of open-label daclizumab in multiple sclerosis patients was assessed, but no results are reported in the abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: